Discovery of Balovaptan, a Vasopressin 1a Receptor Antagonist for the Treatment of Autism Spectrum Disorder-Reference-Cited by-同舟云学术

Discovery of Balovaptan, a Vasopressin 1a Receptor Antagonist for the Treatment of Autism Spectrum Disorder

Published:2020-01-17 Issue:4 Volume:63 Page:1511-1525
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Schnider Patrick¹^ORCID,Bissantz Caterina¹,Bruns Andreas¹,Dolente Cosimo¹,Goetschi Erwin¹,Jakob-Roetne Roland¹,Künnecke Basil¹,Mueggler Thomas¹,Muster Wolfgang¹,Parrott Neil¹,Pinard Emmanuel¹,Ratni Hasane¹^ORCID,Risterucci Céline¹,Rogers-Evans Mark¹,von Kienlin Markus¹,Grundschober Christophe¹

Affiliation:

1. Pharmaceutical Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Grenzacherstrasse 124, 4070 Basel, Switzerland

Funder

F. Hoffmann-La Roche

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.9b01478

Reference50 articles.

1. Vasopressin Receptors

2. V1a vasopressin receptors maintain normal blood pressure by regulating circulating blood volume and baroreflex sensitivity

3. The hypothalamic–neurohypophysial system regulates the hypothalamic–pituitary–adrenal axis under stress: An old concept revisited